Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6137124 | 0.98 | MEN1 (0.47) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL68581 | 0.88 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL5512697 | 0.86 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL29473284 | 0.86 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7142299 | 0.86 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL30205268 | 0.84 | MEN1 (0.58) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL15415006 | 0.78 | MEN1 (0.63) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL31230424 | 0.76 | ALDH1A1 (0.41) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL31230416 | 0.76 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL18322825 | 0.76 | PDPK1 (0.46) | MAPTHPGDKDM4EMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | claimed |
| US-12378202-B2 | Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2025-01-09 | — | — | US | disclosed |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-09-07 | — | — | US | disclosed |
| CN-114950558-B | Bipiperidine skeleton tetradentate nitrogen-containing manganese catalyst and method for catalyzing hydrocarbon molecule benzyl site selective oxidation by using same | 陕西师范大学 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023122781-A2 | TETRAHYDROBENZOAZEPINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-5693635-A | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS RENAL ABSORPTION OF WATER; CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME | AMERICAN CYANAMID COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5686445-A | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0709386-A1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5512563-A | TREATING DISEASES CAUSED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994018169-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD4 | MEN1 4368/4885KMT2A 2238/4885MAPT 2965/4885 |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | BRCA1, TP53, BCCIP | MEN1 295/4885KMT2A 1749/4885MAPT 4721/4885 |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HDAC11, HDAC1, HDAC6 | MEN1 1965/4885KMT2A 130/4885MAPT 1867/4885 |
| US-12378202-B2 | Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD4 | MEN1 4368/4885KMT2A 2238/4885MAPT 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.